血塞通注射液、格列齐特与二甲双胍联合治疗2型糖尿病肾病的疗效及安全性分析

Analysis on Efficacy and Safety of Xuesaitong Injection and Gliclazide Combined with Metformin in the Treatment of Type 2 Diabetic Nephropathy

目的 :分析血塞通注射液、格列齐特与二甲双胍联合治疗2型糖尿病肾病的疗效及安全性。方法:选择2016年4月—2017年4月我院收治的2型糖尿病肾病患者90例为研究对象,按随机数字表法分为对照组与干预组,各45例。对照组采用格列齐特(60 mg,tid)与二甲双胍(0.5 g,tid)治疗,干预组在对照组基础上加用血塞通注射液(10 mL加入到250 mL 0.9%氯化钠注射液中,bid)治疗,比较两组临床指标、血液流变学指标、代谢指标及不良反应发生情况。结果 :干预组临床指标、凝血水平、血液流变学指标明显优于对照组,差异有统计学意义(P <0.05);治疗后,两组均未出现任何不良反应。结论 :血塞通注射液、格列齐特与二甲双胍联合治疗2型糖尿病肾病的临床疗效显著,且安全性较高,值得临床推广应用。

Objective: To analyze the efficacy and safety of xuesaitong injection and gliclazide and metformin in the treatment of type 2 diabetic nephropathy. Methods: 90 patients with type 2 diabetic nephropathy who were admitted to our hospital from April 2016 to April 2017 were selected as subjects investigated and randomly divided into control group and intervention group,45 patients in each group. The patients in the control group were treated with gliclazide (60 mg, tid) and metformin (0.5 g, tid). The patients in the intervention group were further treated with xuesaitong injection (10 mL added to 250 mL 0.9% sodium chloride injection, bid). The clinical indexes, hemorheological indexes, metabolic indexes and adverse reactions were compared between the two groups. Results: The clinical indexes, blood coagulation level and hemorheological indexes in the intervention group were significantly better than those in the control group (P<0.05). After treatment, there was no adverse reaction in the two groups. Conclusion: Xuesaitong injection and gliclazide combined with metformin in the treatment of type 2 diabetic nephropathy have significant clinical efficacy and high safety, and are worthy of clinical generalization and application.